Jefferies Global Healthcare Conference
Logotype for Natera Inc

Natera (NTRA) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Natera Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Quarter and leadership

  • Revenue grew 42% YoY ex-true-ups; Signatera posted another record growth quarter, with sequential ASP gains and strong organic gross margin performance.

  • Full-year revenue guidance was reset to above $3B; Signatera was described as addressing an estimated $20B annual opportunity, with roughly $1B penetrated to date.

  • CEO Steve is stepping down after eight years in the role; Solomon Moshkevich, a long-tenured leader across women’s health, Prospera and oncology, is taking over in a warm handoff.

Revenue target and Signatera growth

  • The $6B-plus 2029 revenue target assumes continued execution, including modest growth in women’s health and organ health and Signatera patient growth broadly in line with the rolling four-quarter average of quarterly unit growth.

  • Signatera’s 2029 ASP target is $1,450 versus roughly $1,290 currently; nine MolDX coverage applications are in flight, and broader tumor coverage could add $200–$300 to ASP.

  • MolDX responses typically take 9–12 months; further ASP opportunities include Medicare Advantage reimbursement compliance, commercial coverage in biomarker states and possible NCCN guideline adoption in colorectal and breast cancer.

  • New patient starts were described as strong and increasing; they represent roughly 10%–15% of quarterly clinical MRD volume, while existing-patient retention and tests per patient are expected to follow established patterns.

Signatera Genome roadmap

  • Signatera Genome expands baseline sequencing from the exome to the whole genome, enabling a broader set of personalized targets; phased and structural variants are intended to improve sensitivity without meaningful additional false positives.

  • Outcomes trials are expected to read out in 2027 and 2028, with samples also analyzed using the newer assay; the resulting evidence may accelerate demand for Signatera Genome.

  • Genome-backbone test COGS are currently higher than exome COGS; temporary cost increases are expected to last a couple of quarters, while phased variants add little cost.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Natera